Santen Pharmaceutical Co., Ltd Noto Plant (manufacturer, responsible for manufacturing in bulk, primary and secondary packaging, quality control)

The drug is intended for the treatment of increased intraocular pressure in patients with open-angle or pseudoexfoliative glaucoma, if the use of beta-blockers alone is insufficient.

Dosage form: drops, ophthalmic solution

ATC: S01ED51